SUMMARY Auranofin, a member of a class of compounds with disease modifying activity, was given to arthritic rats to determine if it could reverse the abnormal plasma concentrations of fibronectin (Fn), C reactive protein (CRP), and albumin, which were unaffected by treatment with non-steroidal anti-inflammatory drugs (NSAIDs). When auranofin was orally administered for two weeks to adjuvant induced arthritic rats it significantly inhibited swelling of the injected and non-injected paws at doses of 3 and 10 mg/kg. Rocket electroimmunoassay measurement of plasma proteins in normal, arthritic, and auranofin treated arthritic rats indicated that auranofin at 10 mg/kg significantly decreased (by 77%/0) the abnormally high concentration of arthritic rat plasma Fn, though it had no effect on Fn concentrations when administered to normal rats. CRP, which was raised approximately twofold above normal in arthritic rats, was reduced by 56% after treatment of arthritic rats with auranofin at 10 mg/kg, though CRP concentrations in normal rats were unaffected by auranofin treatment. Depressed albumin concentrations in arthritic rats were significantly enhanced (by 30%) by dosing with 10 mg/kg of auranofin. At the 3 mg/kg dose, auranofin did not significantly change plasma concentrations of Fn, CRP, and albumin in arthritic rats. At a dose of 10 mg/kg, however, auranofin, in addition to inhibiting chronic systemic paw inflammation, also altered abnormal concentrations of plasma Fn, CRP, and albumin in the adjuvant arthritic rat, thus distinguishing auranofin from standard NSAIDs we have previously tested.
another model of inflammation, the carrageenan induced pleurisy macrophage model developed by Ackerman et patients.
In contrast with the typically high concentrations of plasma CRP associated with RA, 27 Antibody against rat Fn and CRP was prepared by mixing the purified proteins (2 mg/ml) 1:1 with complete or incomplete Freund's adjuvant. On -days 1 and 8 a 0-5 ml aliquot of the complete adjuvant (plus Fn or CRP) was injected subcutaneously into each of two sites along the flank of a goat. The procedure was repeated on day 15 using Fn or CRP plus incomplete adjuvant. On day 22 the goat received one subcutaneous and one intramuscular injection of 0-5 ml antigen plus incomplete adjuvant. Ten days later 250-500 ml of whole blood was taken from the jugular vein. Goat, antirat Fn or CRP antibody was obtained from the serum by affinity chromatography. '9 42 The antibody specificity against Fn or CRP was monitored by immunoelectrophoresis and showed no cross reactivity with rat albumin or C3b or serum amyloid protein. (9) utg/ml CRP). 
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